Antidepressant use in Australia and Sweden-A cross-country comparison.
Australia
Sweden
antidepressant agent
drug utilisation
pharmacoepidemiology
prescription
Journal
Pharmacoepidemiology and drug safety
ISSN: 1099-1557
Titre abrégé: Pharmacoepidemiol Drug Saf
Pays: England
ID NLM: 9208369
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
05
07
2020
revised:
11
10
2020
accepted:
15
10
2020
pubmed:
25
10
2020
medline:
25
11
2021
entrez:
24
10
2020
Statut:
ppublish
Résumé
To compare the dispensed use of antidepressants in Australia and Sweden. We analysed publicly available data from Australia and Sweden on dispensed use of antidepressants from 2006 to 2018. The dispensed use of antidepressants has increased in both Australia and Sweden. Australia had a more rapid increase resulting in a higher total use. The utilisation profile was similar in both countries; SSRIs were the most commonly used group, "other antidepressants" were the group that increased the most, and seven of the eight most used substances were the same. There were differences in which antidepressants were most used, with the three most prescribed antidepressants being escitalopram, sertraline, and venlafaxine in Australia; and mirtazapine, sertraline, and citalopram in Sweden. Dispensed use of antidepressants has increased remarkably in both Australia and Sweden between 2006 and 2018. Although similar with regard to economic status and health care system, use of antidepressants differs between both countries. This may be a result of a combination of factors related to medical, contextual and policy evidence. The differences displayed in this study may reflect varying accessibility of treatments, national programmes enhancing mental health literacy in the population, clinical prescribing guidelines and timing of approval of new antidepressants.
Substances chimiques
Antidepressive Agents
0
Serotonin Uptake Inhibitors
0
Citalopram
0DHU5B8D6V
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
409-417Informations de copyright
© 2020 John Wiley & Sons Ltd.
Références
Organisation for Economic Co-operation and Development. Health at a Glance 2019 [Internet]. 2019 [23 Jan 2020]. Available from https://www.oecd-ilibrary.org/docserver/4dd50c09-en.pdf?expires=1586417366&id=id&accname=guest&checksum=95047F3A17768397C2836BB96500222B
National Board of Health and Welfare. Allt fler får antidepressiva läkemedel [Internet]. Stockholm: Socialstyrelsen; 2019 [2019 Oct 7]. Available from https://www.socialstyrelsen.se/om-socialstyrelsen/pressrum/press/allt-fler-far-antidepressiva-lakemedel/
Hollingworth SA, Burgess PM, Whiteford HA. Affective and anxiety disorders: prevalence, treatment and antidepressant medication use. Aust N Z J Psychiatry. 2010;44(6):513-519.
Brett J, Karanges EA, Daniels B, et al. Psychotropic medication use in Australia, 2007 to 2015: changes in annual incidence, prevalence and treatment exposure. Aust N Z J Psychiatry. 2017;51(10):990-999.
Stephenson CP, Karanges E, McGregor IS. Trends in the utilisation of psychotropic medications in Australia from 2000 to 2011. Aust N Z J Psychiatry. 2013;47(1):74-87.
Carlsten A, Waern M, Ekedahl A, Ranstam J. Antidepressant medication and suicide in Sweden. Pharmacoepidemiol Drug Saf. 2001;10(6):525-530.
Gardarsdottir H, Heerdink ER, van Dijk L, Egberts AC. Indications for antidepressant drug prescribing in general practice in The Netherlands. J Affect Disord. 2007;98(1-2):109-115.
Institute for Health Metrics and Evaluation. Global Burden of Disease Study 2017 [Internet]. 2017 [3 Feb 2020]. Available from http://ghdx.healthdata.org/gbd-results-tool
Australian Institute of Health and Welfare. Mental health services in Australia [Internet]; 2020, Febuary 12; Canberra: AIHW. Available from https://www.aihw.gov.au/reports/mental-health-services/mental-health-services-in-australia
Swedish Medical Products Agency. Depression, ångestsyndrom och tvångssyndrom hos barn och vuxna-behandlingsrekommendation: Information från Läkemedelsverket. Läkemedelsverket. 2016;27(6):26-59.
National Board of Health and Welfare. Nationella riktlinjer för vård vid depression och ångest-stöd för styrning och ledning [Internet]; 2017 [2020 Jan 28]; Socialstyrelsen. Available from https://www.socialstyrelsen.se/globalassets/sharepoint-dokument/artikelkatalog/nationella-riktlinjer/2017-12-4.pdf
Psychotropic Expert Group. Therapeutic guidelines: psychotropic. Version 7. [Internet]. Therapeutic Guidelines Limited; 2013 [2020 Jan 28]. Available from https://tgldcdp-tg-org-au.ezproxy.library.uq.edu.au/topicTeaser?guidelinePage=Psychotropic&etgAccess=true
Khawam EA, Laurencic G, Malone DA Jr. Side effects of antidepressants: an overview. Cleve Clin J Med. 2006;73(4):351-361.
Munoz-Arroyo R, Sutton M, Morrison J. Exploring potential explanations for the increase in antidepressant prescribing in Scotland using secondary analyses of routine data. Br J Gen Pract. 2006;56(527):423-428.
Mossialos E, Wenzl M, Osborn R, Sarnak D. 2015 International Profiles of Health Care Systems: Canadian Agency for Drugs and Technologies in Health; 2016.
Slade T, Johnston A, Oakley Browne MA, Andrews G, Whiteford H. 2007 National Survey of mental health and wellbeing: methods and key findings. Aust N Z J Psychiatry. 2009;43(7):594-605.
WHO Collaborating Centre for Drug Statistics Methodology Norwegian Institute of Public Health. ATC/DDD Index [Internet]. [3 Feb 2020]. Available from https://www.whocc.no/atc_ddd_index/?code=N06A&showdescription=no
Therapeutic Goods Administration. Product and Consumer Medicine Information [Internet]. [updated 20 Feb 2020]. Available from https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/PICMI?OpenForm&t=&q=&r=https://www.pbs.gov.au/medicine/item/2417f-2418g-2429w
The Swedish Association of the Pharmaceutical Industry AB. ATC-register, N06A Antidepressiva medel [Internet]. Farmaceutiska specialiteter i Sverige [29 Jan 2020]. Available from https://www.fass.se/LIF/atcregister?userType=0&atcCode=N06A
Australian Government Department of Health. The Pharmaceutical Benefits Scheme [Internet]. [cited 2020 19 Jun]. Available from http://www.pbs.gov.au/pbs/home
Drug Utilisation Sub-Committee of the Pharmaceutical Benefits Advisory Committee. Australian Statistics on Medicines [Internet]. Pharmaceutical Benefits Scheme [5 Feb 2020]. Available from http://www.pbs.gov.au/info/statistics/asm/australian-statistics-on-medicines
Australian Government Department of Health. Pharmaceutical Benefits Scheme and Repatriation Pharmaceutical Benefits Scheme Section 85 Supply Data [Internet]. Pharmaceutical Benefits Scheme [3 Feb 2020]. Available from http://www.pbs.gov.au/info/statistics/dos-and-dop/dos-and-dop
Australian Bureau of Statistics. 3101.0-Australian Demographic Statistics, Jun 2019 [Internet]. 2019 [3 Feb 2020]. Available from https://www.abs.gov.au/AUSSTATS/abs@.nsf/second+level+view?ReadForm&prodno=3101.0&viewtitle=Australian%20Demographic%20Statistics~Jun%202019~Latest~19/12/2019&&tabname=Past%20Future%20Issues&prodno=3101.0&issue=Jun%202019&num=&view=&
The Pharmaceutical Benefit Scheme. Browse by Body System, N06A Antidepressants [Internet]. [29 Jan 2020]. Available from http://www.pbs.gov.au/browse/body-systemdepth=3&codes=n06a#n06a
National Board of Health and Welfare. Statistikdatabas för läkemedel [Internet]. Socialstyrelsen; [24 Feb 2020]. Available from https://sdb.socialstyrelsen.se/if_lak/val.aspx
Nomesco. Nowbase, MED26 ATC-code N06A, Sales of antidepressants, 2004-2017 [Internet]. [13 Feb 2020]. Available from http://pxweb.fujitsu.dk/pxweb/en/Nowbase/Nowbase__NOMESCO%2004%20medicine/MED26%20N06A%20-%20Antidepressants.px/?rxid=c7e95ba0-c0e2-40d3-a2f7-1a49496b9748
Lag (1996:1157) om läkemedelskommittéer. (1996).
Australian Psychological Society. APS National Schedule of Recommended Fees (not including G.S.T.) and item numbers* for psychological services [Internet]. 2018 [2020 Mar 30]. Available from https://www.psychology.org.au/getmedia/af30b47d-ef39-49c2-8116-6d20ed1dc828/18APS-2018-19-APS-IS-SRF-P1-a.pdf
Forns J, Pottegård A, Reinders T, et al. Antidepressant use in Denmark, Germany, Spain, and Sweden between 2009 and 2014: incidence and comorbidities of antidepressant initiators. J Affect Disord. 2019;249:242-252.
Harro J, Aadamsoo K, Rootslane L, et al. Comparison of psychotropic medication use in the Baltic countries. Nord J Psychiatry. 2020;74(4):301-306.
De Maeseneer JM, van Driel ML, Green LA, van Weel C. The need for research in primary care. Lancet. 2003;362(9392):1314-1319.
Partridge B, Lucke J, Hall W. Over-diagnosed and over-treated: a survey of Australian public attitudes towards the acceptability of drug treatment for depression and ADHD. BMC Psychiatry. 2014;14:74.
Dahlberg KM, Waern M, Runeson B. Mental health literacy and attitudes in a Swedish community sample-investigating the role of personal experience of mental health care. BMC Pub Health. 2008;8:8.
Patana P. Mental Health Analysis Profiles (MhAPs): Sweden; 2015.
Beyond Blue. About Beyond Blue [Internet]. 2020 [May 10, 2020]. Available from https://www.beyondblue.org.au/